A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer
The postoperative survival of early-stage non-small-cell lung cancer (NSCLC) patients remains unsatisfactory. In this review, we examined the relevant literature to ascertain the prognostic effect of related indicators on early-stage NSCLC. The prognostic effects of the epidermal growth factor recep...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/18/4561 |
| _version_ | 1797580883845185536 |
|---|---|
| author | Weibo Cao Quanying Tang Jingtong Zeng Xin Jin Lingling Zu Song Xu |
| author_facet | Weibo Cao Quanying Tang Jingtong Zeng Xin Jin Lingling Zu Song Xu |
| author_sort | Weibo Cao |
| collection | DOAJ |
| description | The postoperative survival of early-stage non-small-cell lung cancer (NSCLC) patients remains unsatisfactory. In this review, we examined the relevant literature to ascertain the prognostic effect of related indicators on early-stage NSCLC. The prognostic effects of the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), mesenchymal–epithelial transition (MET), C-ros oncogene 1 (ROS1), or tumour protein p53 (TP53) alterations in resected NSCLC remains debatable. Kirsten rat sarcoma viral oncogene homologue (KRAS) alterations indicate unfavourable outcomes in early-stage NSCLC. Meanwhile, adjuvant or neoadjuvant EGFR-targeted agents can substantially improve prognosis in early-stage NSCLC with EGFR alterations. Based on the summary of current studies, resected NSCLC patients with overexpression of programmed death-ligand 1 (PD-L1) had worsening survival. Conversely, PD-L1 or PD-1 inhibitors can substantially improve patient survival. Considering blood biomarkers, perioperative peripheral venous circulating tumour cells (CTCs) and pulmonary venous CTCs predicted unfavourable prognoses and led to distant metastases. Similarly, patients with detectable perioperative circulating tumour DNA (ctDNA) also had reduced survival. Moreover, patients with perioperatively elevated carcinoembryonic antigen (CEA) in the circulation predicted significantly worse survival outcomes. In the future, we will incorporate mutated genes, immune checkpoints, and blood-based biomarkers by applying artificial intelligence (AI) to construct prognostic models that predict patient survival accurately and guide individualised treatment. |
| first_indexed | 2024-03-10T22:57:23Z |
| format | Article |
| id | doaj.art-81ec99cc95c14a3ea1283605b7fa9fb6 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T22:57:23Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-81ec99cc95c14a3ea1283605b7fa9fb62023-11-19T09:55:32ZengMDPI AGCancers2072-66942023-09-011518456110.3390/cancers15184561A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung CancerWeibo Cao0Quanying Tang1Jingtong Zeng2Xin Jin3Lingling Zu4Song Xu5Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin 300052, ChinaDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin 300052, ChinaDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin 300052, ChinaDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin 300052, ChinaDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin 300052, ChinaDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin 300052, ChinaThe postoperative survival of early-stage non-small-cell lung cancer (NSCLC) patients remains unsatisfactory. In this review, we examined the relevant literature to ascertain the prognostic effect of related indicators on early-stage NSCLC. The prognostic effects of the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), mesenchymal–epithelial transition (MET), C-ros oncogene 1 (ROS1), or tumour protein p53 (TP53) alterations in resected NSCLC remains debatable. Kirsten rat sarcoma viral oncogene homologue (KRAS) alterations indicate unfavourable outcomes in early-stage NSCLC. Meanwhile, adjuvant or neoadjuvant EGFR-targeted agents can substantially improve prognosis in early-stage NSCLC with EGFR alterations. Based on the summary of current studies, resected NSCLC patients with overexpression of programmed death-ligand 1 (PD-L1) had worsening survival. Conversely, PD-L1 or PD-1 inhibitors can substantially improve patient survival. Considering blood biomarkers, perioperative peripheral venous circulating tumour cells (CTCs) and pulmonary venous CTCs predicted unfavourable prognoses and led to distant metastases. Similarly, patients with detectable perioperative circulating tumour DNA (ctDNA) also had reduced survival. Moreover, patients with perioperatively elevated carcinoembryonic antigen (CEA) in the circulation predicted significantly worse survival outcomes. In the future, we will incorporate mutated genes, immune checkpoints, and blood-based biomarkers by applying artificial intelligence (AI) to construct prognostic models that predict patient survival accurately and guide individualised treatment.https://www.mdpi.com/2072-6694/15/18/4561non-small-cell lung cancerearly-stagesurgerybiomarkersprognosis |
| spellingShingle | Weibo Cao Quanying Tang Jingtong Zeng Xin Jin Lingling Zu Song Xu A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer Cancers non-small-cell lung cancer early-stage surgery biomarkers prognosis |
| title | A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer |
| title_full | A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer |
| title_fullStr | A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer |
| title_full_unstemmed | A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer |
| title_short | A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer |
| title_sort | review of biomarkers and their clinical impact in resected early stage non small cell lung cancer |
| topic | non-small-cell lung cancer early-stage surgery biomarkers prognosis |
| url | https://www.mdpi.com/2072-6694/15/18/4561 |
| work_keys_str_mv | AT weibocao areviewofbiomarkersandtheirclinicalimpactinresectedearlystagenonsmallcelllungcancer AT quanyingtang areviewofbiomarkersandtheirclinicalimpactinresectedearlystagenonsmallcelllungcancer AT jingtongzeng areviewofbiomarkersandtheirclinicalimpactinresectedearlystagenonsmallcelllungcancer AT xinjin areviewofbiomarkersandtheirclinicalimpactinresectedearlystagenonsmallcelllungcancer AT linglingzu areviewofbiomarkersandtheirclinicalimpactinresectedearlystagenonsmallcelllungcancer AT songxu areviewofbiomarkersandtheirclinicalimpactinresectedearlystagenonsmallcelllungcancer AT weibocao reviewofbiomarkersandtheirclinicalimpactinresectedearlystagenonsmallcelllungcancer AT quanyingtang reviewofbiomarkersandtheirclinicalimpactinresectedearlystagenonsmallcelllungcancer AT jingtongzeng reviewofbiomarkersandtheirclinicalimpactinresectedearlystagenonsmallcelllungcancer AT xinjin reviewofbiomarkersandtheirclinicalimpactinresectedearlystagenonsmallcelllungcancer AT linglingzu reviewofbiomarkersandtheirclinicalimpactinresectedearlystagenonsmallcelllungcancer AT songxu reviewofbiomarkersandtheirclinicalimpactinresectedearlystagenonsmallcelllungcancer |